News | Proton Therapy | October 29, 2018

Victoria Advisory Committee for Proton Therapy Launched at ASTRO 2018

Committee features experts in radiation and proton therapy from around the world to advance proton therapy care, ease adoption of new technologies

Victoria Advisory Committee for Proton Therapy Launched at ASTRO 2018

October 29, 2018 — At the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, IBA announced the launch of the Victoria Advisory Committee, a consortium of worldwide radiation therapy experts to help define the future of proton therapy care.

The clinical community and IBA are joining forces to push the boundaries of proton therapy even further and treat all patients that could benefit from it. The Victoria Advisory Committee consists of clinical experts from the world’s leading cancer centers specializing in radiation and proton therapy and includes:

  • Jürgen Debus, M.D., Ph.D., Heidelberg University Hospital;
  • Tom Depuydt, Ph.D., ParTICle/UZ Leuven;
  • Adam Dicker, M.D., Ph.D., Jefferson University Hospitals;
  • Peyman Kabolizadeh, M.D., Ph.D., Beaumont Health Proton Therapy Center;
  • Zuofeng Li, D.Sc., University of Florida Health Proton Therapy Institute;
  • Carlos Vargas, M.D., Mayo Clinic Arizona, and other experts from prestigious institutions such as the University of Pennsylvania.

The clinical experts will help define future roadmaps as well as help to make clinical adoption easy for technologies such as:

  • Editable workflow — establishing a workflow framework to increase the treatment efficiency while navigating the growing treatment complexity;
  • Arc Therapy- — introducing rotational arc proton therapy as an additional treatment option; and
  • Adaptive technology — making online adaptive therapy a reality for proton therapy.
     

The first meeting of the Victoria Advisory Committee took place around the time of ASTRO 2018.

Kabolizadeh, medical director, Beaumont Health Proton Therapy Center, said, “We have recently announced the first irradiation of a Spot Scanning Proton Arc Therapy plan in our facility in Royal Oak, Mich., and we were excited to share the very promising initial results with the leading experts in the field during that meeting.”

Li, physics director, University of Florida Health Proton Therapy Institute (UFHPTI), stated: “As one of the pioneers in proton therapy with over 7,700 patients treated, we are delighted to contribute with our longstanding experience to advance proton therapy to the next level focusing on better treatment quality, reliability and efficiency.”

For more information: www.iba-worldwide.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.